Mantomed

Memantine Hydrochloride, the active ingredient in Mantomed, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is used to treat Alzheimer’s disease in adult patients with moderate to severe cognitive impairment.

GNH USA supplies Mantomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mantomed belongs to the NMDA receptor antagonist class and is indicated for the treatment of dementia related to Alzheimer’s disease.

Alzheimer's disease (moderate to severe): helps maintain cognition and functional abilities in patients with established disease.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Fatigue: feeling of tiredness. - Hypertension: modest increase in blood pressure.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin reaction. - Hepatic dysfunction: abnormal liver enzymes. - Cardiac arrhythmia: irregular heart rhythm.

Mantomed should be used with caution in patients with specific health considerations.

Renal impairment: dose may need adjustment. History of seizures: monitor for increased seizure activity. Cardiovascular disease: use cautiously due to possible blood pressure changes. Concomitant NMDA antagonists: avoid additive neurotoxicity. Pregnancy: safety unknown; avoid unless clearly needed. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Other NMDA antagonists: additive central nervous system effects. - Anticholinergic agents: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Diuretics: potential increase in memantine plasma levels. - Antihypertensives: possible potentiation of blood‑pressure lowering effects.